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ABSTRACT
Allergic manifestations are one of the clinical signs of primary immunodeficiency diseases (PID). In this review, the common allergic manifestations 
of PID are summarized, and their main differential characteristics and treatment approaches are outlined. Allergic manifestations occur more often 
in patients with combined immunodeficiencies with or without associated or syndromic features. In patients with PID they usually are present in the 
1st year of life, may be among the first symptoms of PID, and are commonly manifested by eczema and increased immunoglobulin IgG levels. Often 
the skin barrier function is not impaired in patients with eczema and PID, although some diseases (such as Comel-Netherton syndrome) do affect 
skin barrier function. There is usually no correlation between IgE levels and the severity of allergic skin manifestations. Allergic-like manifestations 
in PID patients include urticaria-like rash and angioedema. Urticaria-like rash is associated with autoinflammatory disorders, which are commonly 
accompanied by fever, and caused by a neutrophilic infiltrate in the dermis. Angioedema in hereditary angioedema patients is caused by high 
bradykinin production. Early differentiation of allergic manifestations in PID from atopic dermatitis and other atopic conditions is very difficult; 
however, it is very important because it influences on treatment methods. A multidisciplinary approach to the management of PID patients, with 
the involvement of immunologists, allergists, and formulation of appropriate treatment improve the prognosis and quality of life of the PID patients.
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INTRODUCTION
Primary immunodeficiency diseases (PID) are a group of disorders 
caused by genetic defects in the immune system that leads to immune 
dysfunction [1]. The most frequent manifestations of PID are severe 
recurrent infections that are caused by unusual organisms and are 
difficult to cure [2,3]. Among other manifestations of PID, there are 
autoimmune diseases, allergic disorders, and malignancy.
Allergic disorders are often manifested by atopy, which typically can 
be present as atopic dermatitis (eczema), allergic rhinitis (hay fever) 
or asthma. The majority of allergic diseases are immunoglobulin IgE 
mediated [4]. At present, almost half of the world’s population suffers from 
allergic diseases. The prevalence of allergic disorders has rapidly increased 
in recent years but is significantly underdiagnosed in some countries [5].
In patients with the normal function of the immune system, infections 
lead to Th1 and Th2 type of immune responses. This also causes the 
development of Tregs, which support a balance between Th1 and Th2 
immune responses, and prevent their harmful effects. In the cases of 
absent or poor Tregs check, the patients become more susceptible to 
allergic or autoimmune disorders [4].
Physicians’ awareness concerning PID is poor among physicians of 
different specialties [6], though an early diagnosis of these diseases is very 
important for preventing the development of complications and improving 
the quality of life of the children with PID. Allergic manifestations of skin 
are often early findings of PID [7]. Thus, it is very important to recognize 
allergic reactions as possible manifestations of PID.
The purpose of this study was to collect and systematize data on PID, 
associated with allergic or allergic-like manifestations for improving 
the early diagnosis of PID.
The novelty of the study is in the complex assessment of allergic and 
allergic-like manifestations in children with PID.
ALLERGIC MANIFESTATIONS OF PID
PID are classified into nine major groups: Combined immunodeficiencies 
without non-immunologic phenotypes; combined immunodeficiencies 
with syndromic features; predominantly antibody deficiencies; diseases 
of immune dysregulation; congenital defects of phagocyte number, 
function, or both; defects of innate immunity; autoinflammatory 
disorders; complement deficiencies; and phenocopies of PID [2].
In the International Union of Immunological Societies Expert 
Committee for Primary Immunodeficiency classification [2], allergic 
manifestations are mentioned for 11 diseases (Table 1) and allergic-
like manifestations for 6 diseases (Table 2). While mammalian sterile 
20-like 1 (MST1) deficiency is included in this classification, its allergic 
manifestations were not listed (Table 3).
Clinical symptoms of dedicator of cytokinesis 8 (DOCK8) deficiency 
include atopic dermatitis, allergies, cutaneous viral infections, 
cutaneous staphylococcal abscesses, recurrent sinopulmonary 
infections, and malignancy [8,9]. Laboratory findings indicate 
elevated serum IgE levels, hypo-IgM, T cell lymphopenia, and 
eosinophilia [9]. The DOCK8 gene mutation was discovered in 
2009 [10], allowing to isolate it as a separate nosological form, 
since it was previously known as autosomal recessive hyper-
IgE syndrome [11]. The authors reported about 21 patients with 
confirmed DOCK8 deficiency they had followed for 20 years [9]. 
Dermatitis in patients with DOCK8 deficiency occurred in 91% of 
cases and was characterized by severe course. Substantial food and 
environmental allergies were registered in 71% of DOCK8-deficient 
patients, while nearly 50% had asthma [9].
Another study reported a case of moderate atopic dermatitis, food 
allergy to cow’s milk protein and hen eggs, and extensive molluscum 
contagiosum in a 3-year-old patient with DOCK8 deficiency [12].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i11.29059
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DOCK8 deficiency impacts immune cell function, migration, and affects 
innate and adaptive immune responses [13]. It also causes persistence of 
B cells in germinal centers, early T-cell death, and decreased natural killer 
cell cytotoxicity [14]. The median IgE levels in DOCK8 deficiency were 
5201 IU, low IgM levels observed in 62% of patients, and lymphopenia 
in 20% of patients, mainly due to low CD4+ and CD8+T-cell number [15].
Omenn syndrome
Omenn syndrome is another severe combined immunodeficiency 
that is manifested by allergic symptoms. It is an autosomal recessive 
disease characterized by erythroderma, desquamation, alopecia, 
chronic diarrhea, failure to thrive, lymphadenopathy, eosinophilia, 
hepatosplenomegaly, and elevated serum IgE levels [16]. The disease is 
caused by mutations in the RAG1 or RAG2 genes [17]. Omenn syndrome 
is an inflammatory condition caused by multiple genetic abnormalities, 
which can significantly impair T-cell development in the thymus. It is 
a genetically heterogeneous condition, meaning that patients with 
similar phenotypes may have different underlying genetic defects. It 
was linked to mutations in ARTEMIS, ADA, ILRA2, ILRA7, CHD7, DNA 
ligase 4, and other novel homozygous mutations [18,19].
Omenn syndrome is associated with the virtual absence of B cells, low 
IgG, IgA, and IgM levels [20]. The presence and expansion of oligoclonal 
autoreactive T cells lead to lymphocytosis [21]. Activated and antigen-
Table 1: Primary immunodeficiencies associated with allergic manifestations (according to the classification from the international 
union of immunological societies expert committee for primary immunodeficiency)
Disease Inheritance Allergic 
manifestations
Laboratory findings Other clinical manifestations
Combined immunodeficiencies




decreased, low CD27+memory 
B cells, low IgM, low NK cells 
with impaired function
Recurrent infections; extensive cutaneous 
viral and bacterial (staph.) infections, 
susceptibility to cancer
Omenn syndrome Erythroderma, 
eosinophilia, increased 
IgE.
Restricted T cell repertoire, 
and impaired function, B cells 
normal or decreased, serum Ig 
decreased
Adenopathies, hepatosplenomegaly
Combined immunodeficiencies with associated or syndromic features




responses to anti-CD3, 
decreased IgM: antibody to 
polysaccharides particularly 
decreased; often increased IgA
Thrombocytopenia with small platelets; 
lymphoma; autoimmune disease; 
IgA nephropathy; bacterial and viral 
infections. 
WIP deficiency AR Eczema increased IgE. Reduced, defective lymphocyte 
responses to anti-CD3, low 
B cell.





AD Often de 
novo defect
Eczema, elevated IgE; Normal Th-17 and T follicular 
helper cells decreased, 
switched and non-switched 
memory B cells are reduced; 
BAFF level increased, 
specific antibody production 
decreased
Distinctive facial features (broad 
nasal bridge), osteoporosis, fractures, 
scoliosis, delay of shedding of primary 
teeth, hyperextensible joints, bacterial 
infections (skin and pulmonary 
abscesses, pneumatoceles) due to 
Staphylococcus aureus, candidiasis, 
aneurysm formation
Tyk2 deficiency AR Elevated IgE Multiple cytokine signaling 
defect
Susceptibility to intracellular 




AR Atopic diathesis, 
elevated IgE.
Switched and non-switched B 
cells are reduced, elevated IgA, 
antibody variably decreased
Congenital ichthyosis, bamboo hair, 
increased bacterial infections, failure to 
thrive
STAT5b deficiency AR Eczema Modestly decreased T-cell. Growth-hormone insensitive dwarfism, 
dysmorphic features, lymphocytic 
interstitial pneumonitis, autoimmunity
Predominantly antibody deficiencies
Selective IgA deficiency Variable May have allergies IgA decreased/absent Usually asymptomatic; may have recurrent 
infections; or autoimmune disease





XL Eczema, Elevated IgE. Lack of (and/or 
impaired function of) 
CD4+CD25+FOXP3+regulatory 
T cells (Tregs), elevated IgA
Autoimmune enteropathy, early-onset 
diabetes, thyroiditis, hemolytic anemia, 
thrombocytopenia. 
Autoinflammatory disorders
PLAID AD Cold urticaria Mutations cause 
activation of IL-1 pathway, 
hypogammaglobulinemia
Recurrent sinopulmonary infections, skin 
granuloma.
Data [2]. AD: Autosomal dominant, AR: Autosomal recessive, BAAF: B‑cell activating factor, XL: X‑linked, WAS: Wiskott–Aldrich syndrome, PLAID: PLCγ2‑associated 
antibody deficiency and immune dysregulation, DOCK8: Dedicator of cytokinesis 8, IL: Interleukin, Tyk2: Tyrosine kinase 2, IPEX: Immune dysregulation, 
polyendocrinopathy, enteropathy X-linked, FOXP3: Forkhead box protein 3
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stimulated T helper 2 (TH2) cells produce high levels of interleukin 4 
(IL-4) and IL-5. These cytokines caused eosinophilia and elevated IgE 
levels [17].
Wiskott-Aldrich syndrome (WAS)
Wiskott-Aldrich syndrome can also be manifested by eczema and 
increased IgE levels [2]. Eczema in patients with WAS is a feature of the 
clinical triad which also includes microthrombocytopenia and recurrent 
infections [22]. WAS is an X-linked disorder. The genes associated with 
WAS are on the short arm of the X chromosome (Xp11.22-p11.23). At 
present, there are more than 300 identified unique mutations resulting 
in WAS; this produces a wide variability of clinical symptoms [23]. 
The majority of the mutations are missense mutations, followed by 
nonsense, splice-site, and short deletion mutations.
Eczema was registered in 80% of the patients with WAS [22]. It is often 
identified during the 1st month of life and fits the diagnostic criteria for 
atopic dermatitis. The eczema usually has widespread involvement, but 
primarily appears on the face, scalp, in the flexures, and diaper area. It is 
followed by progressive lichenification. Eczema can be complicated by 
secondary infections such as cellulitis and abscess and gets better with 
age [24]. Eczema can be associated with other IgE-mediated allergic 
diseases, such as urticaria, food allergies, and asthma.
Deficiency in the WAS protein (WASP)-interacting protein (WIP 
deficiency)
Deficiency in the WAS protein (WASP)-interacting protein (WIP 
deficiency) is a novel autosomal recessive PID [25]. Clinical features of 
WIP deficiency are similar to WAS, but the WAS sequence and mRNA 
levels are normal. WAS protein (WASP) cannot be detected in the cells 
of these patients. WASP is almost completely complexed with the WIP 
in T cells [26]. The main function of WIP is stabilization of WASP and 
prevention of its degradation [25]. Allergic manifestations in these 
patients are presented by eczema and increased IgE levels [2]. An 
eczematous rash appears in the 1st day of life [26].
Hyper-IgE syndrome (Job’s syndrome)
Hyper-IgE syndrome is an autosomal dominant disease (AD-HIES). 
Allergic manifestations of this disease are well known and well 
described [2,7]. The disease is characterized by eczema, recurrent 
bacterial infections (skin and pulmonary abscesses, pneumatoceles), 
mucocutaneous candidiasis, elevated serum IgE levels, and 
Table 2: Primary immunodeficiencies associated with allergic-like manifestations
Disease Inheritance Allergic-like 
manifestations
Laboratory findings Other clinical manifestations
Autoinflammatory disorders




FCAS AD Non-pruritic 
urticaria
Defect in cryopyrin, involved in 
leukocyte apoptosis and NF‑κB signaling 
and IL-1 processing
Arthritis, chills, fever, and 
leukocytosis after exposure to cold 
NOMID or CINCA AD Neonatal onset rash Defect in cryopyrin, involved in 
leukocyte apoptosis and NF‑κB signaling 
and IL-1 processing
Chronic meningitis, and arthropathy 
with fever and inflammation
TRAPS AD Rash Mutations of 55-kDa TNF receptor 
leading to intracellular receptor 
retention or decreased soluble cytokine 
receptor available to bind TNF
Recurrent fever, serositis, and ocular 
or joint inflammation
Blau syndrome AD Rash Mutations in nucleotide binding site of 
CARD15, possibly disrupting interactions 
with lipopolysaccharides and NF‑κB 
signaling
Uveitis, granulomatous synovitis, 
camptodactyly, and cranial 
neuropathies; 30% of the patients 
develop Crohn’s disease
Complement deficiencies
C1 inhibitor deficiency AD HAE Spontaneous activation of the 
complement pathway with consumption 
of C4/C2 spontaneous activation of 
the contact system with generation of 
bradykinin from high molecular weight 
kininogen
Data from [2]. MWS: Muckle–Wells syndrome, FCAS: Familial cold autoinflammatory syndrome, NOMID: Neonatal-onset multisystem inflammatory disease, 
CINCA: Chronic infantile neurologic cutaneous and articular syndrome, TRAPS: TNF receptor-associated periodic syndrome, SNHL: Sensorineural hearing losses, 
IL: Interleukin
Table 3: Other primary immunodeficiencies associated with allergic manifestations
Disease Inheritance Allergic manifestations Laboratory findings Other clinical manifestations
PGM3 deficiency AR Atopic dermatitis, multiple 
allergies, and asthma elevated IgE 
level
Cytopenias, mostly lymphopenia 
and neutropenia.
Recurrent infections, neurologic 
abnormalities
MST1 deficiency AR Eczematous dermatitis [59] Decreased/increased proportion 
of terminal differentiated 
effector memory cells (TEMRA), 
low naïve T cells, restricted T 
cell repertoire in the TEMRA 
population, and impaired T cells 
proliferation.
Recurrent bacterial, viral, and candida 
infections; intermittent neutropenia; 
EBV-driven lymphoproliferation; 
lymphoma; congenital heart disease, 
autoimmune cytopenias; HPV 
infection. 
PGM3: Phosphoglucomutase 3, EBV: Epstein–Barr virus, HPV: Human papillomavirus
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eosinophilia [2]. The severity of the disease can vary. AD-HIES is 
associated with heterozygous mutations of signal transducer and 
activator of transcription three genes (STAT3; 17q21.31) [27].
Neonatal rash is among first clinical features of this disorder. The skin 
barrier function in the AD-HIES patients is not impaired, in contrast with 
the AD patients that experience changes of skin barrier function [28].
AD-HIES affects not only the immune system but also connective tissue, 
skeleton, and dental development [29]. Distinctive facial features are a 
characteristic feature of this syndrome. Increased risk of autoimmune 
and lymphoproliferative diseases is also associated with this disease.
Increased IgE levels up to 2000 U/ml are common in patients with 
AD-HIES, often higher than 5000 U/ml. Despite the high levels of 
IgE, the patients with AD-HIES suffer from a deficiency of allergic 
sensitization [27]; this can be explained by a normal skin barrier 
function and confirm its significance in the development of allergic 
sensitization.
In a study, the patients with STAT3 mutations experienced weakened 
allergic reactions, in particular, food allergies and anaphylaxis [30].
Since eczema can be among the early symptoms in patients with AD-
HIES, timely differentiation of HIES from atopic dermatitis is difficult, 
extremely important due to the differences in treatment [31].
Human tyrosine kinase 2 (Tyk2) deficiency
Human tyrosine kinase 2 (Tyk2) deficiency was initially registered 
in a Japanese patient as a syndrome with elevated IgE and with 
susceptibility to intracellular infections [2,32]. Another study reported a 
Turkish patient with Tyk2 deficiency without hyper-IgE syndrome [33]. 
Additional six patients from different countries with Tyk2 deficiency 
suffered from mycobacterial and viral infections without hyper-IgE 
syndrome [34]. Tyk2 deficiency leads to multiple cytokine signaling 
defects,  first  of  all  to  impaired production of  IFN‑α/β  and  IL‑12  that 
causes susceptibility to intracellular infections [34]. The leukocytes 
and fibroblasts respond normally to IL-6, which can explain normal 
IgE levels in these patients. The main clinical manifestations of Tyk2 
deficiency are mycobacterial and/or viral infections.
Comel-Netherton syndrome
Comel-Netherton syndrome is an autosomal recessive genodermatosis. 
Skin manifestations in these patients appear at birth or during the 
1st week of life. Typical ailments include congenital ichthyosiform 
erythroderma, atopic diathesis, and a hair-shaft abnormality known as 
trichorrhexis invaginata [35].
Skin inflammation, leading to scaling and exfoliation, and erythroderma, 
an atopic diathesis complicated by infections, sepsis, and dehydration 
are the disorders that can be life threatening. Dehydration caused 
by corneocyte barrier dysfunction can cause extensive metabolic 
abnormalities and hypernatremia [36].
Mutations of the both copies of serine protease inhibitor of kazal 
type 5 (SPINK5) gene cause Comel-Netherton syndrome [37]. SPINK5 
products, such as lymphoepithelial kazal-type-related inhibitor (LEKTI), 
and tissue kallikreins (KLKs) balance serine proteases/inhibitors in 
skin and effect skin barrier function and desquamation [38]. SPINK5 
mutations result in truncated LEKTI; thus, LEKTI in patients with 
Comel-Netherton syndrome can be of different length, depending on 
the location of mutations. Clinical manifestations correlate with LEKTI 
domain deficiency in patients with Comel-Netherton syndrome [38]. 
The studies have also proved that deregulated epidermal protease 
activity is linked to atopic dermatitis [39]. These studies point to new 
targets for treatment intervention.
Food allergy, especially to peanuts, eggs, and fish often persists 
in patients with Comel-Netherton syndrome. The majority of 
patients have an atopic predisposition, with a family history of 
asthma, atopic dermatitis or hay fever. Serum IgE levels are typically 
increased, sometimes exceeding 10.,000 IU/mL [39]. Specific IgE 
antibodies to environmental and food allergens can be detected, and 
hypereosinophilia can be present in the patients.
STAT5b deficiency
STAT5b deficiency is an autosomal recessive disorder. It is characterized 
by short stature and recurrent pulmonary infections: Bacterial 
pneumonia or opportunistic infections (hemorrhagic Varicella, herpes 
zoster, and Pneumocystis jiroveci) [40-42]. Other clinical signs include 
dysmorphic features and a high-pitched voice. Short stature develops 
in these patients since STAT5b is involved in growth hormone induced 
signaling [41]. In addition, STAT5b is involved in the intracellular 
signaling cascade of IL-2 and IFN-gamma and causes immunodeficiency, 
typically T cell lymphopenia. Immune dysregulation is also manifested 
by eczema and autoimmunity.
Selective IgA deficiency
Selective IgA deficiency is the most common PID. The patients may 
be asymptomatic, have recurrent infections, or autoimmune diseases. 
Patients with selective IgA deficiency can also suffer from allergic 
disorders [43,44]. The incidence of allergic manifestations ranges from 
13% [45] to 84% [46] of patients. There is a significant relationship 
between allergy incidence and patient’s age: It is more commonly 
present among younger patients [45]. Other studies reported that low 
IgA levels are associated with atopic diseases not only in children but 
also in adults [47,48]. Allergy in patients with selective IgA deficiency is 
manifested by asthma, atopic dermatitis, allergic rhinitis/conjunctivitis, 
urticaria, drug allergy, and food allergy [46].
Immune dysregulation, polyendocrinopathy, and enteropathy 
X-linked (IPEX) syndrome
Immune dysregulation, polyendocrinopathy, and enteropathy X-linked 
(IPEX) syndrome is caused by inheritable mutations in the forkhead 
box protein 3 (FOXP3) gene and is characterized by the development of 
multiple autoimmune disorders [49]. FOXP3 Treg cells have inhibitory 
functions and are responsible for immune homeostasis and tolerance 
to self- and non-self-antigens [49]. Impaired function of FOXP3+ 
regulatory T cells leads to autoimmune disorders that usually are 
manifested by enteropathy, early-onset diabetes, thyroiditis, hemolytic 
anemia, and thrombocytopenia [2]. Severe diarrhea due to autoimmune 
enteropathy typically begins in the first few months of life and causes 
failure to thrive. Patients with IPEX syndrome frequently suffer from 
eczema. Autoimmune enteropathy and eczema are the main features of 
disease presence after 1 month of age [50]. They are often associated 
with increased IgE levels and eosinophilia in children with IPEX 
syndrome [51].
PLCγ2-associated antibody deficiency and immune dysregulation 
(PLAID)
PLCγ2‑associated  antibody  deficiency  and  immune  dysregulation 
(PLAID) belongs to the group of autoinflammatory disorders and 
is characterized by cold urticaria, recurrent bacterial infections, 
autoimmunity, and skin granuloma development [52]. Cold urticaria 
in PLAID patients is common, and develops rapidly, within minutes 
after contact with cold; it resolves after warming up. Skin rash in 
cases of physical urticaria is caused by mast cell activation and 
mediator release [53,54]. Sometimes prolonged cold contact can cause 
anaphylaxis [52]. The patients frequently have a family history of 
atopy [53].
Phosphoglucomutase 3 (PGM3) deficiency
Phosphoglucomutase 3 (PGM3) deficiency was described in 2014 
as an autosomal recessive disease associated with atopic dermatitis, 
recurrent infections, and increased IgE levels [55-57] (Table 3). 
Atopic dermatitis is a common manifestation; it was observed in all 
17 registered patients with PGM3 deficiency [55,56]. Other allergic 
manifestations such as asthma and multiple allergies can also be 
present [57]. Neurologic abnormalities, such as developmental delay 
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and low IQ, ataxia, dysarthria, myoclonus, and sensorineural hearing 
loss, are common for these patients [57].
MST1 deficiency
Mammalian sterile 20-like (MST1) deficiency is an autosomal recessive 
disease, characterized by bacterial, viral, and candida cutaneous 
infections, and structural cardiac anomalies [57,58]. Eczema-like skin 
lesions beginning in the 1st year of life and mild erythematous skin 
lesions were registered in 3 patients with MST1 deficiency from a single 
family [59].
ALLERGIC-LIKE MANIFESTATIONS OF PID
Some autoinflammatory disorders are characterized by rash, mostly of 
urticaria-like type (Table 3). This group includes cryopyrin-associated 
periodic syndromes (CAPS), represented by three diseases caused 
by a defect in the same gene CIAS1/NLRP3 coding for the protein 
cryopyrin (NALP3): Muckle-Wells syndrome (MWS), neonatal-onset 
multisystem inflammatory disease or chronic infantile neurologic, 
cutaneous, and articular syndrome (NOMID/CINCA), and familial cold 
autoinflammatory syndrome (FCAS) [60,61].
Rash in cases of CAPS is caused by a neutrophilic infiltrate in the 
dermis and is unrelated to mast cell degranulation [60]. Deficit of 
cryopyrin, involved in leukocyte apoptosis and NF‑κB signaling and IL‑1 
processing, is detected in patients with CAPS [2]. All autoinflammatory 
conditions associated with periodic fever, joint pain, and other systemic 
manifestations can also be present. The severity and clinical signs vary 
for each of these diseases. NOMID/CINCA is the most severe condition, 
while FCAS is considered the mildest form [60].
MWS, also known as an urticaria-deafness-amyloidosis syndrome, is 
an autosomal dominant disease, which causes sensorineural deafness 
and recurrent hives, and can lead to amyloidosis. NOMID/CINCA is 
also characterized by progressive hearing loss, but in cases of MWS, 
it develops later. Cognitive and physical disability, bone and joint 
deformities, and short stature are evidenced in NOMID/CINCA [62]. 
Typically in FCAS, but less often in MWS, the symptoms are exacerbated 
by cold and are self-limited within 12–24 hs [61]. In NOMID/CINCA 
patients, the rash is present early: After birth or within the first few 
days or weeks of life. Typically, the rash is not irritating, but in some 
cases, it may be itchy [60].
Despite the differences in the pathogenesis of allergic rash and rash 
in patients with autoinflammatory disorders, in both instances, these 
manifestations look alike and require differential diagnosis. Such 
patients often come to see an allergist. FCAS can be considered as 
cold urticaria, which is an allergic reaction to cold temperatures that 
develops after a few minutes of cold exposure but is never associated 
with fever and joint pain.
TNF receptor-associated periodic syndrome (TRAPS) is caused by a 
mutation of the TNFRSF1A gene and characterized by episodic flares 
that last for 3 weeks or longer with fever, migrated rash, abdominal 
pain, joint pain, periorbital edema, and conjunctivitis [63]. Rash is one 
of the most frequent manifestations of TRAPS, and its occurrence varies 
from 55% [64] to 63% [63] of patients.
Blau syndrome (BS) is caused by the mutation in CARD15/NOD2 gene and 
characterized by early onset granulomatous arthritis, uveitis, and skin 
rash [65]. Clinical manifestations also include fever, malignant systemic 
and pulmonary hypertension, granulomatous large-vessel vasculitis and 
granulomatous inflammation of the liver, kidneys, and lungs.
Skin rash is an early symptom, usually the first manifestation, appearing 
in the 1st year of life, often at the age of 1 month [66]. It is manifested by 
a symmetric dark red, slightly scaly, maculopapular, eczematoid-like or 
lichenoid-like rash with localization first on the face and spreading to 
the trunk and extremities; it resolves spontaneously [67].
C1 inhibitor deficiency, also called hereditary angioedema (HAE), is 
characterized by recurrent episodes of angioedema, without urticaria 
or pruritus [68]. The skin and mucosal tissues of upper respiratory 
and gastrointestinal tracts are often affected [69]. The swelling is self-
limited, although when involves upper respiratory tract, especially 
larynx, it can lead to fatal asphyxiation.
Enormous production of bradykinin, a vasodilator mediator, causes 
the clinical manifestations of HAE [70]. In HAE, histamine and other 
mast cell mediators are not directly involved as they are in allergic and 
urticarial reactions, so antihistamines are not effective.
The above discussion proves that the variability of clinical 
manifestations in PID patients requires a multidisciplinary approach 
to their management [71] with the involvement of immunologists, 
allergists, and other specialists.
TREATMENT APPROACHES
Treatment approaches to the allergic manifestations in PID patients 
and allergic disorders are often different.
Common general treatment strategies of PID include antibiotics, 
intravenous or subcutaneous immunoglobulin (IVIG/SCIG), and 
hematopoietic stem cell transplantation (HSCT).
The treatment of allergy symptoms includes corticosteroids (topical, or 
inhaler, or nasal, or systemic) and/or local application of calcineurin 
inhibitors (tacrolimus and pimecrolimus) [72]. Although PID are often 
associated with viral, bacterial, and candida infections, it is a challenge 
to treat atopic dermatitis and other allergic manifestations by means 
of these drugs, considering their immunosuppressive action. These 
medications are not recommended for long-term use or treatment 
of large surface areas. Skin and other infections should be carefully 
examined. In cases of skin superinfection with Staphylococcus aureus 
in patients with PID and eczema, systemic antibiotics, and antiseptic 
arrangements are used just as in cases of general atopic dermatitis [73].
Long-Term use of emollients for the treatment of skin allergic 
manifestations is helpful in AD-HIES, WAS, Comel-Netherton syndrome, 
and other syndromes associated with eczema [74].
Patients with AD-HIES often require medication to control pruritus. 
Diphenhydramine or a longer-acting antihistamine such as loratadine, 
fexofenadine, desloratadine, or cetirizine can be used for this 
purpose [75].
HSCT is established as the treatment of choice in patients with 
combined immunodeficiencies (DOCK8 deficiency, Omenn syndrome, 
MST1 deficiency, WAS, and WIP deficiency) [76], and the main method 
of treatment in patients with IPEX syndrome [77,78]. Cutaneous 
improvement in the first 6 months after transplant was reported [9,76]. 
IVIG is the treatment of choice in Netherton’s syndrome [79]. This 
therapy also results in relieving skin manifestations.
Immunosuppression with cyclosporine is recommended for dermatitis 
and eosinophilia treatment in patients with Omenn syndrome [80]. 
Interferon gamma can be used to control IL-4 and IL-5 production in 
these patients.
Anti-inflammatory effect of Vitamin D3 supplementation has been 
proved in patients with asthma [81].
Gene therapy is being investigated to treat IPEX syndrome, Omenn 
syndrome, and WAS [77,78,82].
Other approaches are used for the treatment of autoinflammatory 
disorders. Biologic agents that target interleukin-1 are effective for 
treating CAPS [60,62]. Anakinra is approved for patients with NOMID/
CINCA, rilonacept, and canakinumab - for patients with FCAS and MWS.
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Short-term corticosteroids, with or without NSAIDs, are effective for 
treating inflammatory attacks in patients with TRAPS [83]. Anakinra 
and canakinumab have been approved to be effective for treating these 
patients [84], and etanercept has been proved to be effective to some 
extent [85]. TNF inhibition with infliximab or adalimumab was studied 
for the treatment of Blau disease [86].
C1 inhibitor (C1-INH) concentrates or kallikrein inhibitor has been 
established as the treatment of choice in patients with HAE, Types I 
and II [87].
CONCLUSIONS
Allergic manifestations are one of the clinical signs of PID. They take 
place more often in patients with combined immunodeficiencies with 
or without associated or syndromic features.
Allergic manifestations in patients with PID usually are present in the 
1st year of life, they can be among the first symptoms of PID and are 
commonly manifested by eczema and increased IgG levels.
Often the skin barrier function is not impaired in patients with eczema 
and PID, although some diseases (Comel-Netherton syndrome) have a 
negative impact on skin barrier function.
There is usually no correlation between IgE levels and severity of 
allergic skin manifestation.
Allergic-like manifestations in PID patients include urticaria-
like rash and angioedema. Urticaria-like rash is associated with 
autoinflammatory disorders, which are commonly accompanied by 
fever, and caused by a neutrophilic infiltrate in the dermis. Angioedema 
in HAE is caused by high production of bradykinin.
Early differentiation of allergic manifestations due to PID from atopic 
dermatitis and other atopic conditions is very difficult, although it 
is very important because it influences on the choice of treatment 
methods.
A multidisciplinary approach to the management of PID patients 
with the involvement of immunologists, allergists, and prescription of 
appropriate treatment improve the prognosis and quality of life of PID 
patients.
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